HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
Acrivon Therapeutics, Inc. +2.64% Pre
Acrivon Therapeutics, Inc. ACRV | 8.17 8.17 | +2.64% 0.00% Pre |
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:
ACRV) with a Buy and maintains $20 price target.